Table 5 Health gains (QALYs) and net health system cost impacts for 60–64-year-old men (Māori and non-Māori) from the offer of five-years of double therapy involving a statin and an anti-hypertensive, 3% discount rate, and a lifetime horizon*.
Five-year cumulative absolute risk strata | Total QALYs gained (non-Māori) | QALYs gained per 1000 people (non-Māori) | Total QALYs gained (Māori) | QALYs gained per 1000 people (Māori) | Total QALYs gained (ethnic groupings combined) | Net costs in NZ$ million (ethnic groupings combined) | ICER (NZ$ per QALY gained)** |
|---|---|---|---|---|---|---|---|
>20% | 16.7 (13.0 to 20.5) | 289 (225 to 355) | 10.2 (7.70 to 12.7) | 243 (183 to 302) | 26.9 (20.8 to 33.0) | $0.04 ($−0.02 to $0.1) | 1580 (Dominant to $3990) |
>15, ≤20% | 55.4 (43.9 to 67.9) | 203 (160 to 248) | 28.7 (22.3 to 35.4) | 177 (138 to 218) | 84.0 (66.3 to 103) | $0.16 ($−0.09 to $0.39) | 1930 (Dominant to $4960) |
>10, ≤15% | 263 (205 to 319) | 135 (106 to 164) | 91.7 (70.0 to 112) | 124 (94.7 to 152) | 354 (276 to 430) | $1.18 ($−1.5 to $2.55) | $3430 (Dominant to $7860) |
>5, ≤10% | 1410 (1110 to 1720) | 70.0 (54.9 to 85.3) | 179 (139 to 220) | 71.6 (55.7 to 87.9) | 1590 (1250 to 1940) | $14.8 ($4.8 to $25.3) | $9510 ($2740 to $18,000) |
>0, ≤5% | 1330 (1060 to 1610) | 35.5 (28.3 to 43.1) | 32.3 (25.6 to 39.2) | 38.6 (30.6 to 46.9) | 1360 (1090 to 1650) | $34.1 ($18.5 to $51.4 | $25,500 ($12,300 to $41,500) |
